United Therapeutics Corp

UTHR

544.020USD

+22.800+4.37%

Market hours （ET）Quotes delayed by 15 min

United Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

1 / 157

Overall Ranking

4 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

United Therapeutics Corp Highlights

StrengthsRisks

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 36.74% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.18B.

Overvalued

The company’s latest PE is 17.65, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 42.49M shares, decreasing 6.81% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 896.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.70.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

591.265

Target Price

+12.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of United Therapeutics Corp is 9.24, ranking 7 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 790.20M, representing a year-over-year increase of 7.38%, while its net profit experienced a year-over-year increase of 20.91%.

Score

Industry at a Glance

Previous score

9.24

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.80

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of United Therapeutics Corp is 7.74, ranking 49 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 17.65, which is 2.91% below the recent high of 18.17 and 43.79% above the recent low of 9.92.

Score

Industry at a Glance

Previous score

7.74

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 1/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of United Therapeutics Corp is 8.13, ranking 52 out of 157 in the Pharmaceuticals industry. The average price target is 525.00, with a high of 600.00 and a low of 410.43.

Score

Industry at a Glance

Previous score

8.13

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of United Therapeutics Corp is 9.15, ranking 4 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 562.86 and the support level at 486.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.20

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of United Therapeutics Corp is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 98.68%, representing a quarter-over-quarter decrease of 3.65%. The largest institutional shareholder is The Vanguard, holding a total of 4.16M shares, representing 9.48% of shares outstanding, with 3.65% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

4.40M

-0.70%

BlackRock Institutional Trust Company, N.A.

4.26M

-1.77%

Avoro Capital Advisors LLC

2.02M

-14.67%

Wellington Management Company, LLP

1.40M

-3.06%

Renaissance Technologies LLC

Star Investors

2.17M

+2.56%

State Street Investment Management (US)

1.92M

-11.30%

AQR Capital Management, LLC

986.48K

-22.52%

Geode Capital Management, L.L.C.

1.25M

+4.11%

Janus Henderson Investors

454.72K

+61.52%

Rothblatt (Martine A)

666.42K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of United Therapeutics Corp is 9.00, ranking 18 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. United Therapeutics Corp’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

United Therapeutics Corp

UTHR

8.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ligand Pharmaceuticals Inc

LGND

8.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment